Julian Harrison
Stock Analyst at BTIG
(4.76)
# 227
Out of 5,182 analysts
116
Total ratings
64.55%
Success rate
26.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $70 → $98 | $63.92 | +53.32% | 8 | Apr 13, 2026 | |
| AVTX Avalo Therapeutics | Reiterates: Buy | $40 | $13.90 | +187.77% | 4 | Apr 13, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $73 → $78 | $67.06 | +16.31% | 6 | Apr 13, 2026 | |
| CLYM Climb Bio | Reiterates: Buy | $8 | $8.85 | -9.60% | 4 | Apr 8, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $4 | $1.56 | +156.41% | 5 | Apr 7, 2026 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $3.02 | +231.13% | 4 | Apr 1, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Buy | $30 | $18.78 | +59.74% | 6 | Mar 30, 2026 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $46 | $27.52 | +67.15% | 6 | Mar 25, 2026 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $137 | $88.47 | +54.85% | 6 | Mar 23, 2026 | |
| TBPH Theravance Biopharma | Reiterates: Buy | $21 | $16.62 | +26.39% | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $39 | $19.31 | +101.97% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $50 | $38.68 | +29.27% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $24.20 | +44.61% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $125.80 | +19.24% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $6.33 | +168.56% | 3 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $151 | $81.33 | +85.66% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1 | $0.33 | +203.31% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.55 | +40.85% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $14.38 | +164.26% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $6.32 | +596.20% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $15.19 | +301.58% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $104.72 | -21.70% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $3.16 | +374.68% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.55 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $70.29 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.25 | +3,523.19% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.91 | +104.60% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.61 | +1,211.05% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.50 | +29,727.00% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $578.54 | - | 2 | Feb 11, 2022 |
Spyre Therapeutics
Apr 13, 2026
Maintains: Buy
Price Target: $70 → $98
Current: $63.92
Upside: +53.32%
Avalo Therapeutics
Apr 13, 2026
Reiterates: Buy
Price Target: $40
Current: $13.90
Upside: +187.77%
Oruka Therapeutics
Apr 13, 2026
Maintains: Buy
Price Target: $73 → $78
Current: $67.06
Upside: +16.31%
Climb Bio
Apr 8, 2026
Reiterates: Buy
Price Target: $8
Current: $8.85
Upside: -9.60%
Akebia Therapeutics
Apr 7, 2026
Reiterates: Buy
Price Target: $4
Current: $1.56
Upside: +156.41%
Connect Biopharma Holdings
Apr 1, 2026
Reiterates: Buy
Price Target: $10
Current: $3.02
Upside: +231.13%
MoonLake Immunotherapeutics
Mar 30, 2026
Reiterates: Buy
Price Target: $30
Current: $18.78
Upside: +59.74%
Maze Therapeutics
Mar 25, 2026
Reiterates: Buy
Price Target: $46
Current: $27.52
Upside: +67.15%
Apogee Therapeutics
Mar 23, 2026
Reiterates: Buy
Price Target: $137
Current: $88.47
Upside: +54.85%
Theravance Biopharma
Mar 20, 2026
Reiterates: Buy
Price Target: $21
Current: $16.62
Upside: +26.39%
Mar 16, 2026
Maintains: Buy
Price Target: $28 → $39
Current: $19.31
Upside: +101.97%
Mar 5, 2026
Maintains: Buy
Price Target: $49 → $50
Current: $38.68
Upside: +29.27%
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $24.20
Upside: +44.61%
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $125.80
Upside: +19.24%
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $6.33
Upside: +168.56%
Feb 10, 2026
Maintains: Buy
Price Target: $118 → $151
Current: $81.33
Upside: +85.66%
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.33
Upside: +203.31%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $3.55
Upside: +40.85%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $14.38
Upside: +164.26%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.32
Upside: +596.20%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $15.19
Upside: +301.58%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $104.72
Upside: -21.70%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $3.16
Upside: +374.68%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.55
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $70.29
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.25
Upside: +3,523.19%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.91
Upside: +104.60%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.61
Upside: +1,211.05%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.50
Upside: +29,727.00%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $578.54
Upside: -